A Single-Center, Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Emicizumab (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Roche
- 28 Dec 2017 New trial record
- 22 Dec 2017 Planned End Date changed from 28 Apr 2018 to 18 Jul 2018.
- 22 Dec 2017 Planned primary completion date changed from 28 Apr 2018 to 18 Jul 2018.